SecBot SecBot
6-K ·Filed Nov 3, 2026

BNTX

BioNTech SE
NEUTRAL
Impact 5/10
Horizonweeks Processed13d 12h ago SEC0001776985-26-000081
6-K: Earnings release
Actionable Insight • Neutral

The Q3 beat was driven by a one-time €70M milestone and the timing of out-licensing revenue recognition, not by core operating improvement. COVID-19 vaccine revenue continues to decline structurally. The BNT113 PFS miss and the modest DYNASTY-Breast02 results raise questions about pipeline momentum. Watch for the OS readout from AHEAD-MERIT and the upcoming GSK UPC decision on EP626 expected November 4, 2026.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

BNTX drug pipeline →

gotistobart

● Neutral Named in this 6-K
Impact
Phase
Phase 3
Time to market
At least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.
Next catalyst
None dated

What to watchThe key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.

Price Chart

Loading chart...

Executive Summary

BioNTech reported Q3 2026 revenue of €1,289.2M, down 15% YoY from €1,518.9M, driven by a 35% decline in COVID-19 vaccine revenue to €554.3M. The company posted a net profit of €184.5M (€0.73 diluted EPS), versus a net loss of €28.7M in Q3 2025, aided by €683.0M in out-licensing revenue (including a €70M milestone) and lower prior-year patent litigation settlements. R&D spending rose 32% to €748.1M, and the company recorded €223.2M in impairment and restructuring charges. The AHEAD-MERIT Phase 2/3 trial for BNT113 missed its PFS endpoint, while the DYNASTY-Breast02 Phase 3 trial met its primary endpoint with modest PFS benefit but showed limited potential in the current treatment landscape.

Key Financial Metrics

EPS (Adj.)
$1.76
GAAP: $0.73
Revenue
$1.3B
est $1.0B · +24.0% · -15.1% YoY
Free Cash Flow
-$163.4M

Key Facts

  • Q3 2026 revenue €1,289.2M, down 15% YoY (€1,518.9M); COVID-19 vaccine revenue fell 35% to €554.3M
  • Q3 2026 net profit €184.5M (€0.73 diluted EPS) vs net loss €28.7M in Q3 2025
  • Out-licensing revenue of €683.0M included a €70.0M development milestone from an out-licensed R&D program
  • R&D expenses rose 32% to €748.1M, driven by IO/ADC programs and CureVac integration
  • Impairment losses on intangible assets totaled €191.7M in Q3 2026, including €96.0M on a technology asset due to a shift to next-gen AI models
  • Pipeline prioritization costs were €93.1M in Q3 2026, including €42.2M impairment and €19.7M employee-related restructuring
  • Cash, cash equivalents and security investments totaled €16,163.8M as of September 30, 2026
  • AHEAD-MERIT Phase 2/3 trial for BNT113 missed its PFS endpoint; OS evaluation continues
  • DYNASTY-Breast02 Phase 3 trial met its primary endpoint with modest PFS improvement; OS data not mature
  • EP949 patent finally revoked by EPO, reducing Moderna litigation risk in multiple jurisdictions

Financial Impact

Q3 2026 revenue €1,289.2M (down 15% YoY); net profit €184.5M vs loss €28.7M; adjusted net profit €440.9M

revenuenet profitR&D expensesimpairmentscash position

Segment Breakdown

SegmentRevenueGrowth
COVID-19 vaccine$554.3M-35.0%
Out-licensing$683.0M+11.4%
Other revenues$51.9M-1.3%

Risk Factors

  • Ongoing COVID-19 vaccine revenue decline as pandemic demand wanes
  • BNT113 AHEAD-MERIT trial missed PFS endpoint; OS outcome uncertain
  • DYNASTY-Breast02 showed modest PFS benefit with limited commercial potential per management
  • Multiple pending patent litigations (Moderna EP437, Arbutus/Genevant, GSK EP626, Bayer, Translate Bio) create contingent liability risk
  • Rising R&D spend (+32% YoY) and restructuring costs pressure margins
  • European Commission audit of CureVac's €450M advance payment could result in repayment obligation

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
69% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000081
Document: form6-kq32026quarterlyrepo.htm0001776985-26-000081
Document: 0001776985-26-000081-index-headers.html0001776985-26-000081
Document: 0001776985-26-000081-index.html0001776985-26-000081
Document: 0001776985-26-000081.txt0001776985-26-000081
Earnings Context (Synthetic; results releases only)0001776985-26-000081

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 Viewing No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (12h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026